Retrophin Announces Topline Results from Phase 3 FORT Study of Fosmetpantotenate in Patients with PKAN
22 août 2019 06h00 HE
|
Retrophin, Inc.
FORT Study did not achieve its primary or secondary endpoints Company to host conference call and webcast today at 8:30 a.m. ET SAN DIEGO, Aug. 22, 2019 (GLOBE NEWSWIRE) -- Retrophin, Inc....
Retrophin Reports Second Quarter 2019 Financial Results
06 août 2019 16h01 HE
|
Retrophin, Inc.
Top-line results from pivotal Phase 3 FORT Study in PKAN on-track for 3Q 2019 Commercial launch for THIOLA® EC underway following FDA-approval for the treatment of cystinuria Second quarter revenues...
Retrophin to Present at Canaccord Genuity’s 39th Annual Growth Conference
31 juil. 2019 16h30 HE
|
Retrophin, Inc.
SAN DIEGO, July 31, 2019 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ: RTRX) today announced that Eric Dube, Ph.D., chief executive officer, will present at the Canaccord Genuity 39th Annual Growth...
Retrophin to Report Second Quarter 2019 Financial Results
23 juil. 2019 16h30 HE
|
Retrophin, Inc.
SAN DIEGO, July 23, 2019 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ: RTRX) today announced it will report second quarter 2019 financial results on Tuesday, August 6, 2019 after the close of the...
Retrophin to Present at Upcoming Investor Conferences
30 mai 2019 16h30 HE
|
Retrophin, Inc.
SAN DIEGO, May 30, 2019 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ: RTRX) today announced that Company management will present at the following upcoming investor conferences in June: Jefferies...
Retrophin Reports First Quarter 2019 Financial Results
07 mai 2019 16h01 HE
|
Retrophin, Inc.
Top-line results from pivotal Phase 3 FORT Study in PKAN on-track for 3Q 2019 Enrollment ongoing in Phase 3 clinical trials of sparsentan for patients with rare nephropathies FSGS and IgAN Continued...
Retrophin to Present at Upcoming Investor Conferences
05 mars 2019 16h30 HE
|
Retrophin, Inc.
SAN DIEGO, March 05, 2019 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ: RTRX) today announced that Eric Dube, Ph.D., chief executive officer, will present at the following upcoming investor...
Retrophin Recognizes Rare Disease Day® 2019 and Honors People Living with Rare Disease and Their Caregivers
28 févr. 2019 08h00 HE
|
Retrophin, Inc.
SAN DIEGO, Feb. 28, 2019 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ: RTRX) today joins the National Organization for Rare Disorders (NORD), the European Organisation for Rare Diseases (EURORDIS),...
Retrophin Reports Fourth Quarter and Full Year 2018 Financial Results
26 févr. 2019 16h01 HE
|
Retrophin, Inc.
Top-line results from pivotal Phase 3 FORT Study in PKAN expected in 3Q 2019 Two pivotal Phase 3 studies of sparsentan progressing on-track to enable potential first-in-class treatment for both FSGS...
Retrophin to Report Fourth Quarter and Full Year 2018 Financial Results
12 févr. 2019 16h30 HE
|
Retrophin, Inc.
SAN DIEGO, Feb. 12, 2019 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ: RTRX) today announced it will report fourth quarter and full year 2018 financial results on Tuesday, February 26, 2019 after the...